ImmunityBio, Inc.
IBRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,785,119 | $2,553,351 | $2,027,495 | $2,366,544 |
| - Cash | $143,428 | $265,453 | $104,641 | $181,101 |
| + Debt | $789,818 | $726,723 | $723,773 | $645,664 |
| Enterprise Value | $2,431,509 | $3,014,621 | $2,646,627 | $2,831,107 |
| Revenue | $14,745 | $622 | $240 | $934 |
| % Growth | 2,270.6% | 159.2% | -74.3% | – |
| Gross Profit | $14,745 | $622 | $240 | $934 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$264,433 | -$478,663 | -$351,881 | -$320,752 |
| % Margin | -1,793.4% | -76,955.5% | -146,617.1% | -34,341.8% |
| Net Income | -$413,564 | -$583,196 | -$416,567 | -$346,790 |
| % Margin | -2,804.8% | -93,761.4% | -173,569.6% | -37,129.6% |
| EPS Diluted | -0.62 | -1.15 | -1.04 | -0.89 |
| % Growth | 46.1% | -10.6% | -16.9% | – |
| Operating Cash Flow | -$391,236 | -$366,757 | -$337,509 | -$274,419 |
| Capital Expenditures | -$6,888 | -$30,584 | -$78,162 | -$33,563 |
| Free Cash Flow | -$398,124 | -$397,341 | -$415,671 | -$307,982 |